TetraLogic cuts proposed IPO price to $7, deal size is now $46 million

By
A A A

TetraLogic Pharmaceuticals, which is developing small molecule therapeutics for the treatment of cancer, lowered the proposed deal size for its upcoming IPO on Tuesday. The Malvern, PA-based company now plans to raise $46 million by offering 6.5 million shares at $7 per share. The company had previously filed to offer 6.4 million shares at a range of $13 to $15. At the midpoint of the revised range, TetraLogic Pharmaceuticals would raise 49% fewer proceeds than previously anticipated.

TetraLogic Pharmaceuticals, which was founded in 2001, plans to list on the NASDAQ under the symbol TLOG. TetraLogic Pharmaceuticals initially filed confidentially on September 16, 2013. Oppenheimer, Guggenheim Securities and Needham & Co. are the joint bookrunners on the deal. It is expected to price during the week of December 9, 2013.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: TLOG

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

The Pumpkin Carvers
The Pumpkin Carvers                 

Stocks

Referenced

Most Active by Volume

75,151,958
  • $97.46 ▲ 2.89%
46,632,276
  • $71.015 ▲ 2.52%
44,457,755
  • $44.835 ▲ 0.01%
38,490,653
  • $15.54 ▲ 0.13%
33,727,274
  • $3.47 ▼ 0.29%
32,772,584
  • $22.30 ▼ 10.15%
31,779,415
  • $28.655 ▲ 0.47%
31,638,160
  • $11.08 ▲ 12.49%
As of 7/23/2014, 03:07 PM